Aeglea BioTherapeutics, Inc. (AGLE)

Description: Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.

---

Keywords: Cancer Biopharmaceutical Solid Tumors Acid Organic Chemistry Enzymes Metabolism Inborn Errors Of Metabolism Oxidative Stress Cystinuria Glutathione Homocystinuria Methionine

---

Home Page: www.aeglea.com

AGLE Technical Analysis

805 Las Cimas Parkway
Austin, TX 78746
United States
Phone: 512 942 2935

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)